Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has initiated a Phase 1 clinical trial with CTP-354. CTP-354 is a novel GABAA receptor subtype-selective modulator that has demonstrated no sedation at therapeutic doses in preclinical models in contrast to existing GABAA receptor non-selective agonists, such as benzodiazepines. Concert is developing CTP-354 for the potential treatment of spasticity and chronic pain. The Phase 1 single ascending dose study will evaluate the safety, tolerability and pharmacokinetics of CTP-354 in healthy volunteers. The company also intends to conduct a Positron Emission Tomography (PET) study to assess brain receptor occupancy of CTP-354 in healthy volunteers. Concert expects to report top-line results of the Phase 1 single ascending dose study by year-end.
Help employers find you! Check out all the jobs and post your resume.
